6-APDB

# Research Output: 6-APDB

## Chemical Identity

**PubChem CID:** 192599  
**IUPAC Name:** 1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine  
**Common name:** 6-APDB; also called 4-Desoxy-MDA (reflecting its relationship to MDA with the 4-position oxygen replaced by a methylene bridge)  
**Molecular Formula:** C₁₁H₁₅NO  
**Molecular Weight:** 177.24 g/mol  
**Exact Mass:** 177.115364102  
**Canonical SMILES:** CC(CC1=CC2=C(CCO2)C=C1)N  
**InChIKey:** VRNGXHJGMCJRSQ-UHFFFAOYSA-N  
**XLogP:** 1.7 (moderately lipophilic)  
**CAS number:** Not confirmed from API sources; web sources cite 1354634-19-7 (flagged as unverified — see Gaps)  

**Chemical class:** 6-APDB belongs to the phenethylamine, amphetamine, and dihydrobenzofuran (substituted benzofuran) classes. It is the 2,3-dihydro (saturated) analog of 6-APB, and an MDA analog in which the methylenedioxy oxygen at the 4-position of the 3,4-methylenedioxy ring has been replaced with a methylene bridge (Monte et al. 1993 [Ref 9]).  

**Stereochemistry:** The α-methyl group creates a chiral center. No published data specifically addresses the active enantiomer of 6-APDB. Indirect evidence from Johnson et al. 2024 ([Ref 17]) on structurally related benzofuran derivatives (5-MABB/6-MABB) suggests the S-isomer is an efficacious triple releaser (SERT, NET, DAT) while the R-isomer preferentially releases serotonin with diminished dopaminergic activity — a pattern likely applicable to 6-APDB. **FLAG: No stereospecific human or animal data found for 6-APDB itself.**  

**Physical properties:** No melting point, solubility, or salt-form data found in published peer-reviewed literature for 6-APDB specifically. The compound is sold commercially in freebase and HCl salt forms by research chemical suppliers, but no published physicochemical characterization studies were located.  

**Discrepancies with seed data:** The brief lists SMILES and molecular formula as blank — these are now confirmed from PubChem CID 192599 [Ref 19]. The IUPAC name matches. No PubChem CID was listed in the seed data; confirmed as 192599.

---

## Pharmacology

### Mechanism of Action

6-APDB is a triple monoamine releasing agent (TMRA) and uptake inhibitor, acting primarily at the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). Its pharmacological profile is MDMA-like but not identical.

**In vitro transporter data (human transporters, HEK293 cells):**  
Rickli et al. 2015 ([Ref 1]) is the primary published source characterizing 6-APDB's interactions with human monoamine transporters. Key findings from this study (which tested 6-APDB alongside 5-APB, 5-APDB, 6-APB, 4-APB, 7-APB, 5-EAPB, 5-MAPDB, and 2C-B-FLY in the same assay system):

- **Uptake inhibition:** 6-APDB inhibited NA (NET) and 5-HT (SERT) uptake more potently than dopamine (DAT) uptake — the same selectivity profile as MDMA and unlike methamphetamine (which preferentially inhibits DAT).
- **Monoamine release:** 6-APDB acts as a monoamine releaser (substrate-type) at all three transporters, consistent with MDMA mechanism.
- **TAAR1:** 6-APDB interacted with the trace amine-associated receptor 1 (TAAR1), similar to classic amphetamines. TAAR1 agonism modulates monoaminergic signaling.
- **5-HT2A:** 6-APDB is a partial 5-HT2A receptor agonist, consistent with MDMA. This may contribute to mild perceptual and empathogenic effects.
- **5-HT2B:** 6-APDB is a 5-HT2B receptor agonist — unlike MDMA and methamphetamine. This is a significant safety concern; 5-HT2B activation is associated with cardiac valvulopathy and pulmonary arterial hypertension with chronic use (Rickli et al. 2015 [Ref 1]; Rothman & Baumann 2009 [Ref 13]; Rouaud et al. 2024 [Ref 12]).

**In vitro transporter data (rodent synaptosomes):**  
Monte et al. 1993 ([Ref 9]) — the original synthesis paper — characterized 6-APDB's ability to inhibit [³H]serotonin, [³H]dopamine, and [³H]norepinephrine uptake in crude synaptosomal preparations. The abstract confirms compound 6 (6-APDB, described as the "nonoxygenated isostere") "possessed high potency at all uptake sites examined." Web-sourced references (attributed to this same study) cite rodent synaptosome IC₅₀ values of: **SERT ≈322 nM, NET ≈980 nM, DAT ≈1,997 nM**. These specific values could not be independently verified from the paper's abstract alone — **FLAG: These specific IC₅₀ values are web-attributed to Monte et al. 1993 and should be verified against the full paper text before publication.** The ordering (SERT > NET > DAT selectivity) is consistent with the Rickli et al. 2015 human transporter data.

**In vivo behavioral pharmacology:**  
Dolan et al. 2017 ([Ref 2]) directly tested 6-APDB in rodent models:
- Locomotor stimulation in Swiss-Webster mice (open-field assay)
- Full substitution for MDMA discriminative stimulus in Sprague-Dawley rats (MDMA-trained two-lever operant task)
- Partial or no substitution for methamphetamine, cocaine, and DOM discriminative stimuli
- Conclusion: MDMA-like abuse profile expected

For the unsaturated benzofuran analogs 5-APB and 6-APB (direct structural relatives of 6-APDB), Brandt et al. 2020 ([Ref 15]) showed in male rats that these compounds are substrate-type releasers at DAT, NET, and SERT with nanomolar potencies, **at least three-fold more potent than MDA and MDMA** in evoking transporter-mediated release, and produce dose-related elevations in extracellular dopamine and serotonin in vivo. As the saturated (dihydro) version of 6-APB, 6-APDB likely has a somewhat reduced but similar potency profile — though this is class-level inference, not direct 6-APDB in vivo data.

Hill et al. 2023 ([Ref 5]) tested 5-APDB (the closest structural congener of 6-APDB studied in that paper) and found weak locomotor effects but full MDMA-lever substitution, all compounds more potent than MDMA.

**Oeri 2021 ([Ref 16])** reviewed benzofuran class compounds as MDMA alternatives for psychotherapy, noting that 6-APDB's pharmacological profile (serotonergic preference, 5-HT2A partial agonism) is consistent with entactogenic effects but highlights 5-HT2B-related cardiac risk and regulatory barriers as limiting factors.

### Pharmacokinetic Data

No published human pharmacokinetic studies for 6-APDB were found. No data on bioavailability, Tmax, plasma half-life, volume of distribution, or protein binding are available from primary sources.

**Metabolism (class inference):**  
No published metabolic studies exist for 6-APDB. Welter et al. 2015 ([Ref 6]) characterized the metabolism of the structural analog 5-APB in rat urine, identifying 3-carboxymethyl-4-hydroxy amphetamine as the main metabolite. CYP isoenzymes CYP1A2, CYP2B6, CYP2C19, and CYP2D6 were implicated in metabolism of the N-methyl analog 5-MAPB (CYP2B6 was the main contributor to N-demethylation). Plasma concentrations of 5-MAPB in six clinical cases ranged from 5–124 µg/L. These data are extrapolable to 6-APDB only with significant caution given positional isomerism. **FLAG: No published metabolic studies exist for 6-APDB specifically.**

MDMA's pharmacokinetics are better characterized — CYP2D6 is the primary metabolic enzyme for MDMA (Huestis et al. 2025 [Ref, not cited here as MDMA-specific]), which likely applies to 6-APDB given structural similarity, but this is inferential.

**Tolerance (from seed data, no published verification):**  
The seed data reports tolerance buildup with prolonged use, half-life of 25.5 days (tolerance, not drug half-life), full reset at 2.5 months, and cross-tolerances with dopamine and stimulants. **FLAG: No published human or animal tolerance data found for 6-APDB. These values are unverified.**

---

## History

6-APDB was first synthesized and reported in 1993 by **A.P. Monte, D. Marona-Lewicka, N.V. Cozzi, and D.E. Nichols** at Purdue University (Monte et al. 1993 [Ref 9]), published in the *Journal of Medicinal Chemistry* (Vol. 36, pp. 3700–3706, DOI: 10.1021/jm00075a027). The compound was developed as part of a systematic structure-activity relationship investigation of MDA analogs aimed at understanding the role of the methylenedioxy ring oxygen atoms in serotonin and catecholamine transporter interactions, and to identify potentially non-neurotoxic entactogens.

In this original study, 6-APDB was described as compound 6 — the "nonoxygenated isostere" of 5-APDB (compound 5), in which both oxygen atoms of MDA's 3,4-methylenedioxy moiety are absent (replaced by a methylene bridge forming the 2,3-dihydrobenzofuran ring). Behavioral studies showed that benzofuran and indan analogs (including 6-APDB) produced similar discriminative cues in rats trained to discriminate from MBDB, MMAI, and amphetamine.

6-APDB did not enter widespread recreational use until the late 2000s–early 2010s, when it appeared on the European research chemical market as part of the broad wave of NPS sold as "legal high" replacements for MDMA/MDA. The compound entered the EMCDDA early warning system in **2012** (alongside 5-APDB; both reported that year, distinct from 5-APB and 6-APB which appeared in 2010–2011). The "benzofury" compounds attracted significant regulatory attention in the UK.

**Regulatory history:**  
- **10 June 2013 (UK):** 6-APDB was made subject to a Temporary Class Drug Order (TCDO) under the Misuse of Drugs Act 1971, alongside 5-APB, 6-APB, and 5-APDB, following an ACMD assessment [Ref 20]. This brought the substance under immediate legal control while permanent scheduling was considered.  
- **2013 (UK, permanent):** 6-APDB was permanently classified as a **Class B** controlled substance under the Misuse of Drugs Act 1971 using a generic benzofuran definition intended to capture current and future related compounds [Ref 14].  
- UK maximum penalty for supply: 14 years imprisonment and/or an unlimited fine.

---

## Subjective Effects

No controlled human studies have assessed the subjective effects of 6-APDB. All human effect data is derived from anecdotal reports, online communities (Erowid, Bluelight, PsychonautWiki), and regulatory review documents.

The discriminative stimulus studies in rats (Dolan et al. 2017 [Ref 2]; Hill et al. 2023 [Ref 5]) confirm that 6-APDB produces MDMA-like subjective effects in animal models — providing the only controlled evidence that its experiential profile mimics MDMA/MDA rather than classical stimulants or psychedelics.

**Reported subjective effect domains** (user report–derived, as catalogued in the seed data and corroborated by pharmacological class):

*Perception:* Visual haze/noise, tracers, internal and external hallucinations (at higher doses), symmetrical texture repetition, touch enhancement, peripheral misidentification, music enhancement, dreaming enhancement  
*Thinking:* Thought acceleration, creativity enhancement, motivation enhancement (lower doses) and suppression (offset), pattern recognition enhancement, focus enhancement, compulsive redosing urge, cognitive fatigue (comedown), immersion enhancement  
*Transpersonal:* Empathy enhancement (core entactogenic effect), unity and interconnectedness, existential realization  
*Body:* Stimulation, tactile euphoria, wakefulness, appetite suppression, bruxism, pupil dilation, increased sweating, dehydration sensation, temperature dysregulation, increased urination, spontaneous body sensations, bodily lightness, abnormal heartbeat (tachycardia), motor control enhancement  
*Mood:* Empathy enhancement, anxiety suppression, depression (comedown), irritability  
*Miscellaneous:* Sexual arousal (both enhancement and suppression reported); brain zaps (typically during offset/aftereffects); time alteration; mindfulness enhancement  

**Dose ranges (oral, from seed data — user-report sourced, not from controlled studies):**  
- Threshold: 20 mg  
- Light: 30–70 mg  
- Common: 70–100 mg  
- Strong: 100–130 mg  
- Heavy: 130+ mg  

**Duration (oral, from seed data — user-report sourced):**  
- Onset: 30–60 minutes  
- Come up: 30–60 minutes  
- Peak: 2–3 hours  
- Offset: 2–3 hours  
- Total: 6–8 hours  

**FLAG:** These dose and duration values derive entirely from community reports (PsychonautWiki and similar). No controlled human studies exist to confirm them. They are flagged for editorial review per standard policy for emerging substances.

---

## Safety & Toxicity

### Acute Toxicity

No published LD₅₀ data exists for 6-APDB in any species. No human toxicological reference dose has been established. The seed data confirms: "exact toxic dosage is unknown" — this is consistent with the published literature.

No case reports of 6-APDB–specific overdose or acute toxicity have been identified in the indexed literature.

**Comparable structural analog (6-APB) case report:**  
Chan et al. 2013 ([Ref 3]) reported a case of acute psychosis associated with recreational use of 6-APB (the unsaturated analog of 6-APDB) combined with cannabis, with comprehensive toxicological confirmation of 6-APB and THC metabolites. This represents the closest published clinical toxicology case for the structural class. Acute psychosis, agitation, and paranoia are consistent with high-dose serotonergic and dopaminergic stimulation.

### Cardiovascular Risk

A significant and specific risk of the benzofuran class is **5-HT2B receptor agonism**, documented directly for 6-APDB by Rickli et al. 2015 ([Ref 1]). Chronic 5-HT2B activation causes:
- Cardiac valvulopathy (mitral/aortic valve fibrosis) — established from fenfluramine and ergotamine case series
- Pulmonary arterial hypertension
- Mitogenic signaling in valvular interstitial cells via TGFβ pathway

This risk is particularly relevant to frequent/repeated users. The mechanism is well established for serotonin releasers that activate 5-HT2B (Rothman & Baumann 2009 [Ref 13]; Szymanski et al. 2014 [Ref, not separately listed]; Rouaud et al. 2024 [Ref 12]). MDMA itself does not activate 5-HT2B significantly — 6-APDB's 5-HT2B agonism represents an **additional cardiovascular hazard not shared with MDMA**. **FLAG: This is a safety-critical distinction that should be prominently noted in the article.**

### Serotonin Toxicity Risk

As a potent triple monoamine releasing agent with preferential serotonergic activity, 6-APDB carries significant risk of serotonin syndrome when combined with:
- Other serotonin releasers (including MDMA — dangerous; see Interactions)
- SERT inhibitors (SSRIs, SNRIs, tramadol)
- MAOIs (monoamine oxidase inhibitors)
- Triptans, lithium, linezolid

Clinically relevant serotonin toxicity features: agitation, myoclonus, hyperthermia, diaphoresis, tachycardia, tremor, hyperreflexia. Life-threatening: hyperthermia >41.1°C, rhabdomyolysis, DIC, multi-organ failure.

### Neurotoxicity

The motivation for Nichols et al.'s original synthesis of 6-APDB (Monte et al. 1993 [Ref 9]) was to develop non-neurotoxic alternatives to MDA/MDMA by modifying the methylenedioxy ring oxygens. However, **no published studies directly assess whether 6-APDB itself is neurotoxic to serotonergic terminals** in animals or humans. The neurotoxicity studies on MDMA (e.g., Colado et al. 1998 [Ref, not separately listed]) document long-term 5-HT terminal damage mediated by oxidative metabolites — it is unknown whether 6-APDB's metabolic pathway produces similar neurotoxic intermediates. **FLAG: No neurotoxicity data exists for 6-APDB. The "non-neurotoxic" framing from the 1993 paper should not be asserted in article prose without direct evidence.**

### Psychological Risks

- Acute psychosis has been documented for structural analog 6-APB (Chan et al. 2013 [Ref 3])
- Compulsive redosing is listed among the substance's effects, increasing acute toxicity risk
- No published data on long-term psychiatric effects specific to 6-APDB

---

## Harm Reduction

No published harm reduction guidelines exist specifically for 6-APDB. The following is synthesized from class-level evidence and pharmacological data:

**Critical interaction contraindications:**
- **Tramadol + 6-APDB: LETHAL.** Tramadol is both an opioid and a SERT inhibitor. When combined with a serotonin releasing agent like 6-APDB, additive serotonergic burden produces serotonin syndrome risk. Ripple et al. 2000 ([Ref 11]) documented the first reported death from tramadol combined with multiple serotonergic drugs; Baldo 2018 ([Ref 10]) reviewed the mechanistic basis. The combination constitutes a critical danger regardless of dose.
- **MDMA + 6-APDB: DANGEROUS.** Combining two potent serotonin releasers creates stacked serotonergic activity. Dobry et al. 2013 ([Ref 18]) documented the risk of serotonin syndrome from MDMA combined with SSRIs; the risk with another SRA is at least comparable. Luethi & Liechti 2020 ([Ref 4]) note that intoxication reports consistently involve polydrug use with high risk of severe adverse effects and death.
- **MAOIs:** Contraindicated. Combination with irreversible or reversible MAOIs would produce extreme serotonin elevation with potentially fatal outcome.
- **SSRIs/SNRIs:** Contraindicated during active use due to serotonin syndrome risk; also pharmacodynamic antagonism (SSRIs block the SERT-mediated mechanism).

**Testing:**
- 6-APDB is typically undetectable on standard immunoassay drug screens (Luethi & Liechti 2020 [Ref 4]).
- LC-MS/MS or GC-MS required for confirmation.
- Reagent test behavior: not characterized in published literature for 6-APDB specifically. Structural similarity to MDMA/MDA suggests possible reactivity with Marquis reagent (purple-black), but this is inferential.

**Hydration:** As a drug producing heavy sweating and hyperthermia risk, appropriate (but not excessive) water intake is critical. Hyponatremia from over-hydration is a documented risk with MDMA-class compounds.

**Cardiac monitoring:** Due to 5-HT2B agonism, persons with pre-existing cardiac valve conditions or pulmonary hypertension should avoid this class entirely.

---

## Tolerance & Dependence

No published human or animal studies characterize tolerance development or dependence liability for 6-APDB specifically.

From the seed data (unverified): tolerance builds with prolonged/repeated use; tolerance half-life estimated at 25.5 days; full reset estimated at 2.5 months; cross-tolerances with dopamine and stimulants listed.

**Cross-tolerance (class inference):** Serotonin releasing agents share receptor downregulation mechanisms with MDMA — 5-HT receptor downregulation, transporter desensitization. Cross-tolerance with MDMA and other entactogens is likely based on shared mechanism (Luethi & Liechti 2020 [Ref 4]).

**Abuse liability:** Dolan et al. 2017 ([Ref 2]) concluded that 6-APDB's MDMA-like discriminative stimulus profile suggests MDMA-like abuse potential. Brandt et al. 2020 ([Ref 15]) note that benzofurans' greater potency than MDMA increases risk for adverse effects. The seed data rates dependence potential as moderate (physical and psychological). **FLAG: These dependence ratings are not verified against any published study for 6-APDB specifically — they are class-level inferences.**

---

## Interactions

### Tramadol — LETHAL
**Mechanism:** Tramadol inhibits SERT (confirmed in human HEK293 cells; Baldo 2018 [Ref 10]) in addition to its µ-opioid agonism. Combined with 6-APDB (a potent serotonin releaser), the additive serotonergic load substantially elevates risk of serotonin syndrome. Seizure threshold is also lowered by tramadol independently. Ripple et al. 2000 ([Ref 11]) documented the first reported tramadol + serotonergic polypharmacy death. This interaction is classified as **lethal** — the seed data designation is supported by published mechanistic and case evidence.

### MDMA — DANGEROUS
**Mechanism:** MDMA is itself a potent triple monoamine releaser (predominantly serotonergic). Combining MDMA with 6-APDB stacks serotonin-releasing activity from two sources, dramatically elevating risk of serotonin syndrome, hyperthermia, and cardiovascular toxicity. The combination would also additively stress the cardiovascular system (tachycardia, hypertension). Dobry et al. 2013 ([Ref 18]) documented the serotonin syndrome risk from MDMA + serotonergic polypharmacy.

### Alcohol — UNKNOWN
No published data exists on 6-APDB + alcohol pharmacodynamic interactions. Based on class-level reasoning: alcohol may attenuate some stimulant effects while increasing dehydration risk; masks subjective intoxication levels potentially leading to overdose; may elevate neurotoxicity risk (as documented for MDMA + alcohol combinations). **FLAG: No specific data. Class inference only.**

### SSRIs/SNRIs
Not listed in the seed data but pharmacologically critical: SSRIs block SERT (the target for 6-APDB's release mechanism), potentially blunting effects and increasing serotonin syndrome risk. SNRIs add NET inhibition. Both represent contraindications for acute combination use.

### MAOIs
Not listed in seed data but a critical contraindication: combination with MAOIs would produce extreme, potentially fatal serotonin excess.

---

## Legal Status

### United Kingdom
**Class B** controlled substance under the Misuse of Drugs Act 1971. Initially brought under control via Temporary Class Drug Order on **10 June 2013** [Ref 14], alongside 5-APB, 6-APB, and 5-APDB. Subsequently permanently scheduled as Class B using a generic benzofuran definition intended to capture the entire chemical class [Ref 20]. Placed in Schedule 1 to the 2001 Regulations (no recognized medical use; available only under Home Office licence for research). Maximum penalty for supply: 14 years imprisonment and/or unlimited fine.

### United States
6-APDB is **not explicitly scheduled** under the Controlled Substances Act as a named substance. It may be subject to the **Federal Analogue Act (21 U.S.C. § 813)** as a substance with substantially similar chemical structure and pharmacological effects to a Schedule I substance (MDA is Schedule I). Prosecutorial application of the Analogue Act is case-by-case and not automatic.

### Canada
Web sources are inconsistent — one source cites Schedule I, another Schedule III — as an MDA analogue under the Controlled Drugs and Substances Act (CDSA). **FLAG: Canada scheduling status requires direct verification against the CDSA schedule listings. This discrepancy must be resolved before publication.**

### Australia
Australia's "substantially similar" analogue provisions may apply given structural similarity to MDA (a Schedule 9 substance). Explicit scheduling status was not confirmed from published sources.

### Germany
No explicit scheduling information found. Germany's New Psychoactive Substances Act (NpSG, 2016) applies broadly to designer drugs; 6-APDB may fall under this blanket provision. **FLAG: Unconfirmed.**

### Other Jurisdictions
No confirmed information found for Sweden, Japan, Netherlands, or other jurisdictions from published or official sources consulted during this research.

---

## Clinical Trials

No clinical trials for 6-APDB were found on ClinicalTrials.gov. The substance has no recognized medical use and no ongoing research programs using it as an investigational compound.

The broader context of entactogen research for PTSD therapy (which motivates studies of MDMA analogs like those in Oeri 2021 [Ref 16] and Johnson et al. 2024 [Ref 17]) does not currently include 6-APDB as an active candidate, due to its 5-HT2B agonism (cardiac risk) and regulatory status.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief for this substance.

---

## Gaps & Flags

### Safety-Critical Flags (Require Editorial Review Before Publication)

1. **🚨 5-HT2B cardiac risk — substance-specific but severity unquantified.** Rickli et al. 2015 documents 5-HT2B agonism for 6-APDB in vitro. Risk magnitude (dose, duration, frequency required for valvulopathy) is unstudied for 6-APDB specifically.

2. **🚨 Tramadol: LETHAL interaction — mechanistically supported but no 6-APDB-specific case evidence.** The lethal designation is appropriate based on pharmacological mechanism (combined SERT activity + seizure threshold lowering) but no published 6-APDB + tramadol death has been documented in indexed literature.

3. **🚨 IC₅₀ values (SERT 322 nM, NET 980 nM, DAT 1997 nM) — web-attributed to Monte et al. 1993 but NOT independently confirmed.** These appear in Wikipedia and chemical vendor descriptions attributed to rodent synaptosome data from the 1993 paper. The abstract confirms "high potency at all uptake sites" and a serotonin-selective pattern, which is consistent, but the specific numerical values must be verified against the full paper before inclusion in published article text.

4. **🚨 Canada scheduling — CONFLICTING SOURCES.** One web source says Schedule I, another says Schedule III. Cannot be resolved from available sources.

5. **🚨 Tolerance half-life (25.5 days) and full reset (2.5 months) in seed data — no published source found.** These values appear specific to this substance in the DB but no published pharmacodynamic tolerance study exists for 6-APDB. They are presumably community-derived or estimated by analogy.

6. **🚨 No human pharmacokinetic data.** Plasma half-life, bioavailability, Tmax, and metabolism in humans are completely uncharacterized.

### Gaps in Published Evidence

- **No neurotoxicity studies for 6-APDB.** The original 1993 paper's framing as a "non-neurotoxic" alternative should not be asserted without direct evidence — it was a hypothesis at synthesis, not a demonstrated finding.
- **No 6-APDB-specific overdose case reports.** All clinical toxicology data is from structural analogs (6-APB case report) or class-level data.
- **No human pharmacokinetics.** All PK data must be by class inference from MDMA or 5-APB/5-MAPB studies.
- **No stereochemistry data for 6-APDB.** The R vs. S enantiomer differences (documented for structurally related 6-MABB) are extrapolable by inference only.
- **Physical properties uncharacterized in literature.** Melting point, solubility, salt forms not published for 6-APDB.
- **CAS number unconfirmed.** Web sources cite 1354634-19-7 but this was not confirmed via API.
- **Legal status incomplete** for Germany, Sweden, Japan, Australia (analogue provisions possible but not confirmed).
- **5-HT2B functional data.** Rickli et al. 2015 confirms 5-HT2B agonism but the abstract does not provide Emax or EC50 at 5-HT2B for 6-APDB specifically.
- **No published drug-checking reagent test behavior** for 6-APDB documented in peer-reviewed literature.
- **EMCDDA formal risk assessment.** The 2012 first notification to EMCDDA is referenced in secondary sources; the original EMCDDA early warning notification for 6-APDB was not accessed directly.

### Sections Relying Primarily on Structural Analogy or Class Inference

- Metabolism and CYP enzyme data (inferred from 5-APB/5-MAPB)
- In vivo monoamine release potency vs. MDMA/MDA (inferred from 5-APB/6-APB data)
- Tolerance and dependence quantitative values (class inference)
- Serotonin neurotoxicity risk (class-level discussion; no 6-APDB-specific data)
- Harm reduction guidance (class-level from MDMA/entactogen literature)
- Duration and dose ranges (community reports only)